Please ensure Javascript is enabled for purposes of website accessibility

Fresno City Gets Extension in Herndon 4-Story Apartment Case

2 days ago

With Major Heat Risk Forecast, This Is a Good Weekend to Stay Indoors in Fresno

2 days ago

Trump Says Intel Has Agreed to Deal for US to Take 10% Equity Stake

2 days ago

Epstein Associate Maxwell Says She Never Saw Trump Behave Inappropriately

2 days ago

Pew: US Immigrant Population Declines for First Time in Nearly 60 Years

2 days ago

Powell, Citing Jobs Risk, Opens Door to Cuts but Doesn’t Commit

2 days ago

FBI Agents Search Ex-Trump Adviser Bolton’s Home, Source Says

2 days ago

Gaza City Officially in Famine, With Hunger Spreading, Says Global Hunger Monitor

2 days ago

Gavin Newsom’s Redistricting Plan Is on Its Way to Voters. What You Need to Know

3 days ago
UC Davis Uses Antiviral Drug Remdesivir on 'Very Grave' COVID-19 Patient. She's Home Now.
TLBBHMAP3-U010ALB5ANM-348f959abae2-512-300x300-1
By Jim Jakobs, Digital Producer
Published 5 years ago on
April 1, 2020

Share

UC Davis Medical Center received the first case of community transmission of COVID-19 in the U.S. on Feb. 26. Within 24 hours of admission, the female patient’s respiratory status deteriorated.
Because of the severity of her illness, the team received approval from the Food and Drug Administration to treat the woman who is in her 40s with an investigational drug called remdesivir. She has since been discharged and is recovering at home.

Portrait of UC Davis Health professor Angela Haczku, M.D., Ph.D.
“They (the infectious disease doctors) feel that this drug saved the patient’s life.” — Angela Haczku, M.D., Ph.D., UC Davis
The team emphasizes that whether remdesivir is effective against human COVID-19 is not yet known.  Clinical trials funded by the National Institutes of Health and the pharmaceutical industry will be key to analyzing the drug’s effectiveness against coronavirus.
The broad-spectrum antiviral developed by Gilead Sciences Inc. has been tested in humans with Ebola and has shown promise against coronaviruses in animal models according to UC Davis.

What Is Remdesivir and How It Works

Gilead Sciences has initiated two Phase 3 clinical studies to evaluate the safety and “efficacy” of remdesivir in adults diagnosed with COVID-19 following the FDA’s rapid review and acceptance of Gilead’s investigational new drug filing.
“Studies began enrolling patients in March 2020 and will enroll a total of approximately 1,000 patients in the initial phase of the studies, in countries with high prevalence of COVID-19,” Gilead said in an email to GV Wire. “Remdesivir is an experimental medicine that does not have established safety or efficacy for the treatment of any condition.”
Here is a little more information about remdesivir from Gilead’s website:

  • In response to the Ebola outbreaks in West Africa in recent years, Gilead increased the manufacturing of remdesivir to create a stockpile that could be used for future pandemics, as well as a stockpile of the materials used to manufacture remdesivir.
  • Gilead is now using this stockpile to address the supply needed for current compassionate-use requests and ongoing clinical trials.

An article published in The Scientist, a magazine for life science professionals, discusses remdesivir in the following manner:
“Researchers led by Vanderbilt University’s Mark Denison and the University of North Carolina at Chapel Hill’s Ralph Baric showed in 2017 that remdesivir could inhibit replication of the coronaviruses that cause both severe acute respiratory syndrome (SARS) and MERS in human lung cells. The authors also found that the drug reduced viral load and improved respiratory function in a mouse model of SARS.”

Remdesivir Clinical Trials

In a news release, Allison Brashear, dean of the UC Davis School of Medicine said, “Given the urgent need to find an effective treatment for COVID-19, clinical trials are essential for determining, from a scientific standpoint, if remdesivir is safe and effective. With this new study funded by the NIH, UC Davis will be an important contributor to these critical efforts.”


Q&A With UC Davis Professor About the Use of Remdesivir

GV Wire spoke with Angela Haczku MD, Ph.D., of UC Davis to gain insight into what this could mean for other COVID-19 patients. She is the Professor of Medicine Associate Dean for Translational Research.
GV Wire: “How was the patient when she first arrived at the hospital?
“The patient’s status was very, very grave. At the time, when the doctors were desperately trying to help her, this drug worked very well for her. So, I think within a day or two, the course of the disease turned around.”
“Do you think that the drug helped her or do you think it was just absolute blind luck?”
“They (the infectious disease doctors) feel that this drug saved the patient’s life.”
“In California, can the governor approve remdesivir as a treatment without waiting for FDA approval?”
“I know it is a possibility. … I am very very hopeful that very soon we will have this resolved, and very soon we will have some treatment approved (by the FDA) for this disease.”
“By soon, do you mean months or do you mean sooner?”
“I would say one (month), but maybe not too many … could say maybe weeks.”
UC Davis Health has written a paper that’s now published in Clinical Infectious Diseases about their findings.
[covid-19-tracker]

DON'T MISS

What Are Fresno Real Estate Experts Predicting for 2025 and Beyond?

DON'T MISS

First California EV Mandates Hit Automakers This Year. Most Are Not Even Close

DON'T MISS

Why Epstein’s Furious Grip on Washington Holds

DON'T MISS

US Envoy Meets Netanyahu on Lebanon and Syria, Israeli Officials Say

DON'T MISS

Gerry Spence, Renowned for Courtroom Victories and Unique Style, Dead at 96

DON'T MISS

Pentagon Working on Plans for Military Deployment in Chicago, Washington Post Reports

DON'T MISS

Widespread Protests Held in Australia to Support Palestinians

DON'T MISS

VP Vance Says Russia Has Made Significant Concessions Toward Ukraine Peace Deal

DON'T MISS

Israel Strikes Yemeni Capital Sanaa

DON'T MISS

Howard University President to Step Down This Month

DON'T MISS

Hollywood’s Biggest AI Debut? Las Vegas Sphere’s ‘Wizard of Oz’

DON'T MISS

Fresno State Bulldogs Can’t Find Answer for Daniels in Loss at Kansas

UP NEXT

Widespread Protests Held in Australia to Support Palestinians

UP NEXT

Hegseth Authorizes Troops in DC to Carry Weapons

UP NEXT

Texas, Florida Seek to Join Legal Challenge to Abortion Pill

UP NEXT

Wrongly Deported Migrant Abrego Released, May Be Detained Again

UP NEXT

Judge Blocks Trump From Withholding Funds From Los Angeles, Other Sanctuary Cities

UP NEXT

California Cities Lack Unified Response On Homeless Encampments

UP NEXT

Trump Crime Crackdown Deploys Troops in Washington’s Safest Sites

UP NEXT

California Voters Still Support High-Speed Rail, Even If It Never Gets Done

UP NEXT

Trump Says Intel Has Agreed to Deal for US to Take 10% Equity Stake

UP NEXT

I Was Preyed On for My VA Benefits. California Can Stop It

Pentagon Working on Plans for Military Deployment in Chicago, Washington Post Reports

5 hours ago

Widespread Protests Held in Australia to Support Palestinians

5 hours ago

VP Vance Says Russia Has Made Significant Concessions Toward Ukraine Peace Deal

5 hours ago

Israel Strikes Yemeni Capital Sanaa

5 hours ago

Howard University President to Step Down This Month

5 hours ago

Hollywood’s Biggest AI Debut? Las Vegas Sphere’s ‘Wizard of Oz’

5 hours ago

Fresno State Bulldogs Can’t Find Answer for Daniels in Loss at Kansas

18 hours ago

Hegseth Authorizes Troops in DC to Carry Weapons

1 day ago

Texas, Florida Seek to Join Legal Challenge to Abortion Pill

1 day ago

Wrongly Deported Migrant Abrego Released, May Be Detained Again

1 day ago

Why Epstein’s Furious Grip on Washington Holds

Opinion by James Kirchick on August 22, 2025. IT ISN’T JUST MEMBERS OF THE MAGA FAITHFUL WHO ARE FEELING LET DOWN. When the F.B.I. release...

4 hours ago

U.S. financier Jeffrey Epstein appears in a photograph taken for the New York State Division of Criminal Justice Services' sex offender registry March 28, 2017 and obtained by Reuters July 10, 2019. New York State Division of Criminal Justice Services/Handout via REUTERS/File Photo
4 hours ago

Why Epstein’s Furious Grip on Washington Holds

U.S. Ambassador to Turkey and Special Envoy for Syria Thomas Barrack attends an interview with Reuters in Beirut, Lebanon July 22, 2025. (Reuters File)
4 hours ago

US Envoy Meets Netanyahu on Lebanon and Syria, Israeli Officials Say

Former Philippine first lady Imelda Marcos arrives at court with lawyer Gerry Spence. June 28, 1990. (Reuters File)
4 hours ago

Gerry Spence, Renowned for Courtroom Victories and Unique Style, Dead at 96

The Pentagon building is seen in Arlington, Virginia, U.S, April 6, 2023. (Reuters File)
5 hours ago

Pentagon Working on Plans for Military Deployment in Chicago, Washington Post Reports

Demonstrators hold placards as they take part in the 'Nationwide March for Palestine' protest in Sydney, Australia, August 24, 2025. REUTERS/Hollie Adams
5 hours ago

Widespread Protests Held in Australia to Support Palestinians

Firefighters work at the site of a Russian missile strike, amid Russia's attack on Ukraine, in the village of Sknyliv on the outskirts of Lviv, Ukraine August 21, 2025. (Reuters File)
5 hours ago

VP Vance Says Russia Has Made Significant Concessions Toward Ukraine Peace Deal

Smoke billows from the site of Israeli air strikes in Sanaa, Yemen August 24, 2025. REUTERS/Stringer
5 hours ago

Israel Strikes Yemeni Capital Sanaa

Howard University President Ben Vinson III speaks during an election night event for Vice President Kamala Harris', the Democratic presidential nominee, at Howard University in Washington, on Nov. 5, 2024. Howard University said Friday that its president would leave his job at the end of the month after a tenure that lasted only two years, among the shortest stints in the school’s history. (Ruth Fremson/The New York Times)
5 hours ago

Howard University President to Step Down This Month

Search

Help continue the work that gets you the news that matters most.

Send this to a friend